Topic: stress-coping behaviour

Serotonergic psychedelics are emerging as alternative therapies for treatment-resistant depression; however, their hallucinogenic effects may limit their widespread clinical use. Second-generation psychedelics, which lack hallucinogenic effects, are a promising alternative. 2-Bromo-LSD (2-Br-LSD/BETR-001) is an LSD derivative with 5-HT2A partial agonist activity that lacks hallucinogenic effects. Thus, 2-Br-LSD may represent a possible novel therapeutic for treating neuropsychiatric diseases. We assessed the effects of 2-Br-LSD on stress-coping behaviour in mice, using the forced swim test, an